June CÚRAM Co-Director Professor David Brayden appointed to the International Scientific Advisory Board of a Biotech company
Developing new methods of delivering medications to the body without the need for injections is central to the research of Professor David Brayden. Brayden is Professor of Advanced Drug Delivery at the School of Veterinary Medicine, UCD, Fellow of the UCD Conway Institute and Co-Director of CÚRAM, the SFI Research Centre for Medical Devices based at NUI Galway.
Recognition of his expertise in formulations used in the oral delivery of peptides has led to an appointment on an expert scientific advisory board that will work to optimise the development of a unique orally-delivered device to deliver biologics across the stomach that would otherwise be injected.
The advisory board has been formed recently by Biograil ApS, a Copenhagen based biotech company. Biograil achieved proof of concept of the proprietary BIONDD™ Technology in a pre-clinical model. The company is looking to further refine and diversify the platform technology for various biological molecules and will use the SAB to support this process.
The Biograil SAB members are:
- David Brayden, Professor at University College Dublin, Ireland
- Ester Caffarel-Salvador, Science and Business Development Consultant and Lecturer at MIT, MA, United States
- Claus-Michael Lehr, Professor at Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University Saarbrücken, Germany
- Philip Just Larsen, SVP Global Head of Research, Bayer Pharmaceuticals, Germany
Biograil CEO Karsten Lindhardt said: “Biograil is proud to announce support from such a highly experienced group of scientific leaders forming our SAB. We have also already experienced that the variety and complementary expertise the group can provide can be of great future value for the company. We will use input from this amazing group of scientists to help us find the best possible technical and portfolio solutions for progressing our BIONDD™ platform technology.”
Professor Brayden commented: “I am delighted to be appointed to the SAB of Biograil. The company’s unique BIONDD™ device has the potential to deliver important molecules across the stomach wall that otherwise just be injected. Success in this area has the potential to improve the lives of patients through the convenience of oral medications administered in a small device. I look forward to working with the management team and the other members of the SAB to help progress the technology.”
Biograil will continue to develop the SAB according to current needs and plans to involve the SAB members in model development and research activities where appropriate. Biograil will also look for opportunities for non-dilutive funding of research activities with their research partners.
About Biograil Aps
Biograil is a Danish start-up using injection moulding for manufacturing a device in a standard size capsule that can deliver active substances into the gastrointestinal wall. The Biograil device uses a proprietary mechanism to efficiently facilitate the delivery of active substances, i.e., biologics, into the gastrointestinal wall. The team behind Biograil combines seasoned entrepreneurs with long experience in creating successful biotech companies and R&D executives behind the world’s first injection moulded oral tablet approved by the FDA.
Originally published on 2022-03-01 by Biograil (https://www.biograil.com)
About David Brayden
Professor David Brayden is a Full Professor of Advanced Drug Delivery at University College Dublin (UCD) School of Veterinary Medicine and a Senior Fellow of the UCD Conway Institute. His research encompasses questions about how drugs transport across epithelial surfaces of the body ranging from regions of the intestine to the buccal surface. From this, formulations and drug-device combinations can be synthesised, characterised, and tested in in vitro and in vivo bioassays. . His research focuses on clinical applications in diabetes and osteoarthritis.
Current projects include:
-Improving peptide delivery across intestinal epithelia using in vitro and in vivo bioassays
-Nanoparticle formulations of peptides for oral delivery using silica and cell-penetrating peptides
-Nanoparticles formulations for intra-articular injection for osteoarthritis
-Buccal and sublingual delivery of peptides using layer-by-layer patches
Professor Brayden was the Director of the Irish Drug Delivery Research Network from 2007 to 2013, which then became part of the SFI CURAM Centre for Medical Devices. He completed a role as Deputy Coordinator of an EU 7th Framework grant on oral nanomedicines (www.TRANS-INT.eu), 2012-2017. In 2012, he was the first Irish academic to be inducted into the College of Fellows of the Controlled Release Society. In 2017, he became the first Irish academic to be elected as a Fellow of the American Association of Pharmaceutical Scientists. Professor Brayden is the author or co-author of more than 200 research publications and patents. He serves on the Editorial Advisory Boards of Drug Discovery Today, Advanced Drug Delivery Reviews and the Journal of Veterinary Pharmacology and Therapeutics. In 2021, he was appointed first Chief Editor of Frontiers in Drug Delivery. He is a member of Ireland’s National Research Ethics Committee for clinical trials (2021). Professor Brayden was appointed to Full Professor at UCD in 2014.